Uptrend Stocks Impax Laboratories Inc (IPXL); Regulus Therapeutics Inc (RGLS), And Veeva Systems Inc (VEEV)

Posted by George Brook January 9, 2015 0 Comment 937 views


New York, NY – GDP INSIDER  – 01/09/2014.

Impax Laboratories Inc (NASDAQ:IPXL) edged up to a new 52-week high following FDA approval of its treatment for Parkinson’s disease. The regulator finally approved Rytary, a long-acting oral drug that comes in the form of a capsule. The FDA refused to approve Rytary two years ago citing quality control issues at Impax’s manufacturing plants. Therefore, the latest development comes as a big sigh of relief for the company as it can now significantly improve its top-line performance.

Analysts estimate that Impax Laboratories Inc (NASDAQ:IPXL) could generate up to $300 million in annual sale of Rytary.

Rytary is better than the existing standard treatments, and it could give hope of a better life for nearly 1 million people suffering from Parkinson’s disease in the U.S. alone.

Is IPXL Going To Continue To Move Higher Or Are Things About To Turn Around? See What’s In Store For IPXL With A Free Trend Report.

Regulus Therapeutics Inc (NASDAQ:RGLS), under its so-called Clinical Map Initiative, intends to do exploits in 2015. The company is keen to expand its RNA-based drug pipeline and push its drug candidates to marketing approval. The management sees a lot of potential in their portfolio, and they are excited about their scientific and financial strengths in 2015.

Regulus Therapeutics Inc (NASDAQ:RGLS)’s hepatitis C treatment was recently found to be effective in combating the condition.

Will RGLS Continue To Trend Higher Or Are Things About To Crash? See What’s Coming Up Next For RGLS With A Complimentary Trend Analysis Report

Veeva Systems Inc (NYSE:VEEV) edged up almost 5% following a positive mention by Stifel. The stock was upgraded to a “Buy” from a “Hold” and given $36 target price. Stifel initiated coverage of Veeva Systems about 14 months ago with a “Hold” rating and target price of $41. Now the firm admits that the company has performed really well over that period, but there is still more room for upside, although much of the ground seems to have been covered with regards to stock price.

Additionally, Veeva Systems Inc (NYSE:VEEV) is cited by Stifel as having surpassed the initial expectations with regards to R&D. Several other analysts have a positive view on the stock. Such include analysts at Deutsche Bank that also have a “Buy” recommendation on the stock.

Could VEEV Reverse From Here Or Will Momentum Continue? Get A Hint As To What’s Coming Next With A Free Trend Analysis Report

About UltimateStockAlerts

UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.



About George Brook

George Brook covers money and politics for GDP Insider. George is a veteran journalist who has also covered Congress, national political conventions and presidential politics. George also covers the White House as well as economic and domestic policy for GDP insider. George's reporting has won numerous awards, including two Scripps Howard awards, two National Headliners, two Gerald Loeb Awards, as well as honors from Sigma Delta Chi and the National Press Club.

View all post by George Brook Visit author's website

Write Your Comment